Abstract
Although ipilimumab has been shown to improve survival in patients with metastatic melanoma and cause regression of metastatic renal cell carcinoma, the associated immune-related toxicities are of concern. The resultant T cell activation by this monoclonal antibody causes an increased immune response, which has been associated with many immune-regulated adverse effects. One of the most concerning effects is the development of colitis. Upwards to 8% of patients have been reported to develop colitis, with 5% being severe (Grades 3-4). While initial treatment of such adverse effects is generally comprised of supportive and symptomatic treatment, more severe cases warrant the use of high dose steroids. Furthermore, use of anti-TNF agents is usually reserved for those cases that prove to be refractory to steroids. We describe a systematic case review of seven patients who developed gastrointestinal symptoms following initiation of ipilimumab immunotherapy, and present the steps in their evaluation, treatment and outcomes at our institution.
Original language | English (US) |
---|---|
Pages (from-to) | 4373-4378 |
Number of pages | 6 |
Journal | World Journal of Gastroenterology |
Volume | 21 |
Issue number | 14 |
DOIs | |
State | Published - Apr 14 2015 |
Externally published | Yes |
Keywords
- Colitis
- Immune-regulated adverse effects
- Immunology
- Infliximab
- Ipilimumab
ASJC Scopus subject areas
- Gastroenterology